chronic idiopathic urticaria
Dermatology · 2015–2015
1decision
1medicine
1carried consumer input
7individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| omalizumab Treatment of chronic idiopathic urticaria (CIU) in patients who remain symptomatic despite H1 antihistamine treatment and have failed to achieve adequate… | Nov 2015 | Recommended with restriction | 7 individuals |
What the PBS pays
$51M in government benefit over 2024–25, across 82,658 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| omalizumab | $50.8M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.